Testing effectiveness (Phase 2)Looking for participantsNCT06744647
What this trial is testing
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
Who this might be right for
Antibody-Mediated RejectionKidney TransplantationBiopsy-proven Histologic Scores+1 more
Alexion Pharmaceuticals, Inc. 45